The National Health Insurance Serivce was found to have completed pricing negotiations with the companies for the reimbursement of Tagrisso (AZ, osimertinib) and Leclaza (Yuhan, lasertinib) as first-line treatments for non-small cell lung cancer through the risk-sharing agreement (RSA) system.

However, as the two were applied different types of RSA, the actual reimbursed prices of the two drugs are expected to differ somewhat.

According to industry sources on the 1st, AstraZeneca, which owns Tagrisso, and Yuhan Corp, which owns Leclaza, recently completed drug price negotiations with the NHIS.

The pricing negotiations had been ongoing with the NHIS since late September f